The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis

Patients with recurrent or persistent ovarian cancer often have poor prognoses, and their optimal treatment regimen remains unclear. Inhibition of angiogenesis is a valuable strategy for treating ovarian cancer, and the drug pazopanib is a potent, multitarget tyrosine kinase inhibitor. However, trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaping, Fang, Hongming, Wang, Xiaoyan, Wang, Hui, Pan, Guoqiang, Chen, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Gynecological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205118/
https://www.ncbi.nlm.nih.gov/pubmed/36877187
http://dx.doi.org/10.1097/COC.0000000000000999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205118/
https://www.ncbi.nlm.nih.gov/pubmed/36877187
http://dx.doi.org/10.1097/COC.0000000000000999

Ejemplares similares